Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RMBUN
ADC Name
IMGC-936
Synonyms
AEX6003 (S442C)-DGN549; IMGC 936; IMGC-936; IMGC936
   Click to Show/Hide
Organization
ImmunoGen, Inc.; MacroGenics, Inc.
Drug Status
Phase 1/2
Indication
In total 5 Indication(s)
Breast cancer
Phase 2
Clinical Trial
Colorectal cancer
Phase 2
Clinical Trial
Lung cancer
Phase 2
Clinical Trial
Oesophageal cancer
Phase 2
Clinical Trial
Pancreatic cancer
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
2
Structure
Antibody Name
MGA021
  Antibody Info 
Antigen Name
Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9)
  Antigen Info 
Payload Name
DM21-C
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Ala-Ala-Ala
  Linker Info 
Conjugate Type
Undisclosed
Combination Type
tapatansine
Puchem SID
471299317 , 474492571 , 476000966
ChEBI ID
CHEMBL5095346
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04622774
Phase 1
A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04622774  Clinical Status Phase 1
Clinical Description A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.
Primary Endpoint
During dose escalation measure incidence and severity of Treatment Emergent Adverse Events, During dose escalation characterize dose-limiting toxicities (DLTs), During expansion describe the overall response rate.
Other Endpoint
During dose escalation and expansion to characterize study drug concentration and the concentration of anti-drug antibody, During dose expansion describe the duration of response and progression free survival, During dose escalation to describe the objective response rate and duration of response, During dose expansion measure incidence and severity of Treatment Emergent Adverse Events.

   Click to Show/Hide
References
Ref 1 A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors, NCT04622774